Prime Editing has potential to be best-in-class approach for AATD ---- Previously undisclosed program now emerging from within liver platform; ...

Shares of Prime Medicine (NASDAQ: PRME) are surging on Thursday. The move up comes as the S&P 500 and Nasdaq Composite gained ...

Prime Medicine, Inc. announced the launch of a preclinical program targeting alpha-1 antitrypsin deficiency (AATD), a genetic disorder affecting lung and liver function, utilizing their ...

Beam Therapeutics reported promising Phase 1/2 data for BEAM-302, demonstrating durable gene correction for AATD. See why I ...

Completed dosing of first two cohorts in Phase 1/2a REWRITE Clinical Study of KRRO-110 for Alpha-1 Antitrypsin Deficiency (AATD); Interim ...

News of a fresh investigational program was putting some zip into the shares of gene-editing company Prime Medicine (NASDAQ: ...

today unveiled a preclinical program for the treatment of alpha-1 antitrypsin deficiency (AATD), the next program within its liver franchise. Prime Medicine expects to file an investigational new ...

Prime Editing has potential to be best-in-class approach for AATD -- -- Previously undisclosed program now emerging from within liver platform; leverages proprietary, universal liver LNP -- -- High ...

Emmerdale actor Ned Porteous has teased a Tate family return as he'd love to "bring old faces back" amid Joe Tate's deadly ...

Korro Bio, Inc. has completed dosing for the first two cohorts in its Phase 1/2a REWRITE clinical study of KRRO-110, aimed at treating Alpha-1 Antitrypsin Deficiency (AATD), with interim results ...

Prime Medicine and Beam Therapeutics had common origins in gene editing. Now they're both pursuing treatments for the same ...